共被期刊论文引用了3次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CD155表达水平对非小细胞肺癌PD1免疫疗法反应性的影响显示文摘目的探讨CD155表达水平对非小细胞肺癌PD1免疫疗法反应性的影响。方法纳入该院2014年至2018年收治的非小细胞肺癌患者111例,其中男69例、女42例。使用免疫组织化学(IHC)对接受PD1免疫疗法的非小细胞肺癌患者治疗前样本中的CD155蛋白水平进行了表征。对患者的疗效展开评估,分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)与疾病进展(PD)。分析CD155表达水平对疗效的影响。无进展生存期(PFS)Kaplan-Meier曲线和Cox比例风险模型评估CD155与治疗反应之间的关联。比较不同CD155与PDL1表达情况的非小细胞肺癌患者PD1免疫治疗结果。检测非小细胞肺癌组织中免疫浸润的PD1+CD8+T细胞与CD155表达水平的关系。结果根据IHC染色水平,17.12%(19/111)的非小细胞肺癌标本为CD155阴性(评分0+),27.03%(30/111)分类为评分1+,25.23%(28/111)评分为2+,30.63%(34/111)评分为3+。与CD155低表达的肿瘤患者相比(评分为0+、1+),治疗前为CD155高表达的患者(评分为2+、3+)的PD1免疫疗法治疗后表现出较高的SD或PD率,而CR或PR率较低。此外,PD1免疫疗法治疗后6个月内的PD与非小细胞肺癌患者的CD155高表达肿瘤之间存在明显关联。与CD155低表达肿瘤相比,CD155高表达肿瘤患者的中位PFS较短(P<0.05)。肿瘤为PDL1阴性和CD155高表达的患者的RECIST反应较差。接受PD1免疫疗法治疗且肿瘤为PDL1阴性和CD155高表达的患者的6个月PFS率也更低(P<0.05),中位PFS更短(P<0.05)。相比之下,CD155低表达的PDL1阳性肿瘤患者具有更好的PFS结果。PD1+CD8+T细胞的数量与增加的CD155评分有关(P<0.05)。结论CD155的表达水平与非小细胞肺癌组织中免疫浸润的PD1+CD8+T细胞数量具有相关性。此外,靶向CD155途径的治疗可能会改变非小细胞肺癌患者对PD1免疫疗法的反应。 | 肖龙敏 韩文健 吴洪 | 2023 | 国际检验医学杂志2023，44，4： | 1 |
| 2 | Low expression of novel biomarker RCSD1 predicts poor prognosis of lung adenocarcinoma显示文摘Lung adenocarcinoma(LUAD)is a highly malignant lung tumor.In patients with acute lymphoblastic leukemia,the RCSD domain containing 1(RCSD1)gene is translocated and fused with the ABL1 gene to form the RCSD1-ABL1 fusion gene,resulting in high chromosome instability.However,the role of RCDS1 in lung adenocarcinoma remains unclear.This study aimed to evaluate the relationship between the expression of RCSD1 in lung adenocarcinoma,clinical prognosis,biological processes involved,and immune infiltration.The lung cancer explorer database was used to conduct a meta-analysis on the study of RCSD1 in lung adenocarcinoma.We downloaded the sequencing data of the RCSD1 gene in lung adenocarcinoma for prognostic analysis.A receiver operating characteristic(ROC)curve was drawn to assess the diagnostic value of RCSD1 expression in LUAD.Using R language,univariate and multivariate COX regression analysis of the clinical data of RCSD1 in lung adenocarcinoma was carried out.The molecular biological process of RCSD1 in lung adenocarcinoma and the relationship between RCSD1 expression level and immune infiltration were analyzed.Different from the normal lung tissue,the expression level of RCSD1 in lung adenocarcinoma is decreased.Low expression of RCSD1 is related to different clinicopathological characteristics.RCSD1 participates in multiple immune-related pathways and is positively correlated with tumor immune infiltrating cells,immune phenotypes,and immune checkpoint expression.We reveal for the first time the prognostic role of RCSD1 in lung adenocarcinoma.Its mechanism of action may be involved in regulating immune infiltration and can serve as a potential biomarker of lung adenocarcinoma. | Gui-Jin Fang Sheng-Ming Liu | 2022 | Life Research2022，5，1： | 0 |
| 3 | CD155在恶性肿瘤中的免疫调控作用研究进展显示文摘CD155是免疫球蛋白超家族中的一种糖蛋白,在多种恶性肿瘤细胞中表达上调并与患者预后相关。近年来,CD155在肿瘤中的免疫调控作用吸引了广泛关注。CD155可与共刺激受体(CD226)和共抑制性受体(TIGIT和CD96)相互作用调节肿瘤浸润淋巴细胞功能。阻断CD155信号的免疫治疗有望改善肿瘤患者的预后,具有很大的临床应用潜力。本文将从CD155与恶性肿瘤患者预后的关系、免疫调控作用和相关免疫治疗等方面对CD155研究进展进行综述。 | 刘雪 郭凌川 | 2023 | 哈尔滨医药2023，43，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员